https://www.live-feeds.com/feed/roche-returns-to-china-s-adc-powerhouse-hansoh-for-15b-biobucks-pactContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/roche-returns-to-china-s-adc-powerhouse-hansoh-for-15b-biobucks-pacthttps://www.live-feeds.com/feed/roche-returns-to-china-s-adc-powerhouse-hansoh-for-15b-biobucks-pact#u150063Fri, 23 Oct 2026 14:17:21 +0000Pharmaceutical giant Roche has struck a massive agreement with China-based Hansoh Pharmaceutical to develop a portfolio of antibody-drug conjugates. The partnership includes an upfront payment of $400 million and more than $15 billion in potential biobucks and milestone payments. Roche will secure ex-China development rights for two of Hansoh's preclinical antibody-drug conjugates, alongside multiple programs directed at targets proposed by Roche. The collaboration marks a significant expansion of the existing alliance between the two companies, leveraging Hansoh's proprietary in-hou